Top View
- Inebilizumab Reduces Worsening of Disability in Neuromyelitis Optica Spectrum Disorder: Outcomes from the N-Momentum Randomized
- 2019 Annual Report
- Biogen and Gilead Top Tables with Most Valuable R&D Assets
- Earnings Press Release
- View Presentation
- Biopharma Boom Fosters Deal Spree
- Biogen Appealed
- ADUHELM Investor Webcast
- Biogen Inc. - Climate Change 2020
- Regeneron Pharmaceuticals Inc
- Retina Anti-VEGF Biosimilars: How to Prepare for the Coming Wave
- 2015 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
- List of Participants
- Biogen Inc. - Climate Change 2019
- COVID-19 Mrna Vaccines (Pfizer-Biontech and Moderna) in Patients with Multiple Sclerosis: a Statement by a Working Group Convene
- Biogen Idec's Agenda
- Biogen-Idec: Growing a Customer-Focused Supply Chain
- Amgen V. Sanofi
- PX14A6G 1 R325201px14a6g.Htm PROXY MEMORANDUM To: Gilead Sciences, Inc. Shareholders Subject: Shareholder Proposal on an Indepen
- Gilead, Celgene, Biogen Head List of Most Productive Biopharmas
- Pfizer Ventures 2020 in Review
- Gateway Equity Call Premium Fund Investments As of July 31, 2021 (Unaudited)
- The Largest Pharmaceutical Companies Worldwide Analysis of Key Financial Indicators for Fiscal Years 2017, 2018 and 2019 About the Study
- Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's
- Gerald J. Flattmann, Jr
- Schedule 14A
- Senior Staff Biographies
- Biopharmaceutical Industry Pharmd Fellowships
- Smaller Companies Win in Most Valuable Race
- 218 Scientific Abstracts Copyright. on August 31, 2021 at Google Indexer. Protected by Ann Rheum Dis: First
- Biogen, Abbvie Withdraw Multiple Sclerosis Drug Zinbryta About:Reader?Url=
- Biogen Reports Full Year 2019 Revenues of $14.4 Billion
- Biogen Inc. [email protected]
- VIATRIS 2020 Sustainability Report
- Pharmacy Limited Distribution List
- 2020 CONSORTIUM of MS CENTERS PLATFORM ABSTRACTS Disease Assessment and Management
- Mrna COVID-19 Vaccines Do Not Increase the Short-Term Risk of Clinical Relapses in Multiple Sclerosis
- Reuters: Europe's Medicines Regulator Calls for Recall of Biogen, Abbvie
- 20.PG.1 Proxy Memo-Procter and Gamble WEB
- Investor Update Lonza’S Blueprint for the Future
- ANNUAL REPORT October 2020
- Increase of Naïve B Cells, M2 Macrophages and Reduction of Memory B/T Cells During Immune Repopulation at 96 Weeks in CLARITY Assessed by Immune Cell Deconvolution
- Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest
- Regeneron Pharmaceuticals Inc
- Abbvie R&D Deep Dive
- Earnings Press Release
- VIATRIS INC. (Exact Name of Registrant As Specified in Its Charter) Delaware 83-4364296 (State Or Other Jurisdiction (I.R.S
- Biogen and Capsigen Announce Collaboration to Discover and Develop Novel Aav Capsids for Targeted Cns and Neuromuscular Disorders
- DRAFT BIIB Project Dolphin Press Release
- P Number Manufacturer Name P1001 Forest Laboratories, Inc. P1002
- Volunteer Disclosure Report
- Efficacy of Aducanumab
- Item-Level Analysis of Clinical Measures in Patients with Early Symptomatic Alzheimer's Disease Following Treatment with High